Open AccessTime Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019
Author(s) -
Allison W. Kurian,
Kevin C. Ward,
Paul Abrahamse,
Irina Bondarenko,
Ann S. Hamilton,
Dennis Deapen,
Monica Morrow,
Jonathan S. Berek,
Timothy P. Hofer,
Steven J. Katz
Publication year - 2021
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.20.02785
Subject(s) - medicine , chek2 , ovarian cancer , breast cancer , mutyh , msh6 , msh2 , palb2 , genetic testing , oncology , cancer , germline mutation , cancer research , colorectal cancer , dna mismatch repair , genetics , biology , mutation , gene
Genetic testing is important for breast and ovarian cancer risk reduction and treatment, yet little is known about its evolving use.